Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer

Trial Profile

Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Paclitaxel
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record
    • 30 Apr 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 12 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top